Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation

Close metadata

OBJECTIVE

The study goal was the assessment of heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy in stroke patients with varying risk of hemorrhagic transformation (HT).

MATERIAL AND METHODS

It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744). Patients with middle cerebral artery infarction (n=238) were stratified by HT risk with the HTI score. The study outcomes were symptomatic and any HT, and functional outcome measured with the modified Rankin Scale (mRS) on day 90. Favorable outcome was defined as an mRS score of ≤2. Heterogeneous treatment effect analysis was performed using techniques of meta-analysis and the matching-smoothing method.

RESULTS

Heterogeneity of Cerebrolysin treatment effects was moderate (I²=36.98—69.3%, H²=1.59—3.26) and mild (I²=18.33—32.39%, H²=1.22—1.48) for symptomatic and any HT, respectively. A positive impact of the Cerebrolysin treatment on HT and functional outcome was observed in patients with moderate (HTI=1) and high (HTI≥2) HT risk. However, the effect was neutral in those with low risk (HTI=0). In high HT risk patients, there was a steady decline in the rate of symptomatic (HTI=0 vs. HTI≥2: by 3.8%, p=0.120 vs. 14.3%, p<0.001) and any HT (HTI=0 vs. HTI≥2: by 0.6%, p=0.864 vs. 19.5%, p<0.001). Likewise, Cerebrolysin treatment resulted in an overall decrease in the mRS scores (HTI=0 vs. HTI≥2: by 2.1%, p=0.893 vs. 63%, p<0.001) with a reciprocal increase of the fraction with favorable outcome (HTI=0 vs. HTI≥2: by 2% p=0.634 vs. 19.2%, p<0.001).

CONCLUSION

Clinically meaningful heterogeneity of Cerebrolysin treatment effects on HT and functional outcome was established in stroke patients. The Cerebrolysin positive impact was significant in those whose estimated on-admission HT risk was either moderate or high.

Keywords:

Cerebrolysin

hemorrhagic transformation

functional outcome

stroke

reperfusion therapy

alteplase

heterogeneous treatment effects

Authors:

Kalinin M.N.

Kazan State Medical University;
Interregional Clinical Diagnostic Center

ORCID: 0000-0002-3664-6888

Khasanova D.R.

Kazan State Medical University;
Interregional Clinical Diagnostic Center

ORCID: 0000-0002-8825-2346

Received:

29.01.2024

Accepted:

01.02.2024

List of references:

Saver JL. Improving reperfusion therapy for acute ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):333-343. https://doi.org/10.1111/J.1538-7836.2011.04371.X
Otsu Y, Namekawa M, Toriyabe M, et al. Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review. J Neurol Sci. 2020;419:117217. https://doi.org/10.1016/J.JNS.2020.117217
Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012;48(suppl A):3-24. https://doi.org/10.1358/DOT.2012.48(SUPPL.A).1739716
Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;2019(11):CD008900. https://doi.org/10.1002/14651858.CD008900.PUB3
Staszewski J, Stȩpień A, Piusińska-Macoch R, et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion: Study Protocol for a Prospective, Open Label, Single-Center Study With 12 Months of Follow-Up. Front Neurol. 2022;13:910697. https://doi.org/10.3389/FNEUR.2022.910697
Jarosz K, Kojder K, Andrzejewska A, et al. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. Brain Sci. 2023;13(3):507. https://doi.org/10.3390/BRAINSCI13030507
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. https://doi.org/10.1002/14651858.CD007026.PUB7
Lang W, Stadler CH, Poljakovic Z, et al. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013;8(2):95-104. https://doi.org/10.1111/J.1747-4949.2012.00901.X
Guekht A, Vester J, Heiss WD, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurol Sci. 2017;38(10):1761-1769. https://doi.org/10.1007/S10072-017-3037-Z
Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39(4):629-640. https://doi.org/10.1007/S10072-017-3214-0
Beghi E, Binder H, Birle C, et al. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. Eur J Neurol. 2021;28(9):2831-2845. https://doi.org/10.1111/ENE.14936
Khasanova DR, Kalinin MN. Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC Neurol. 2023;23:121. https://doi.org/10.1186/S12883-023-03159-W
Khasanova DR, Kalinin MN. Effects of simultaneous use of Cerebrolysin and alteplase on hemorrhagic transformation of brain infarction and functional outcome in stroke patients: CEREHETIS, a randomized, multicenter pilot trial. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2023;123(8-2):60-69. (In Russ.). https://doi.org/10.17116/JNEVRO202312308260
Wang X, Tsuji K, Lee SR, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35(11-1):2726-2730. https://doi.org/10.1161/01.STR.0000143219.16695.AF
Kelly MA, Shuaib A, Todd KG. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp Neurol. 2006;200(1):38-49. https://doi.org/10.1016/J.EXPNEUROL.2006.01.032
Guan X, Wang Y, Kai G, et al. Cerebrolysin Ameliorates Focal Cerebral Ischemia Injury Through Neuroinflammatory Inhibition via CREB/PGC-1α Pathway. Front Pharmacol. 2019;10:1245. https://doi.org/10.3389/FPHAR.2019.01245
Veinbergs I, Mante M, Mallory M, Masliah E. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl. 2000;59:273-280. https://doi.org/10.1007/978-3-7091-6781-6_29
Teng H, Li C, Zhang Y, et al. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. 2021;32(5):359-366. https://doi.org/10.1097/WNR.0000000000001598
Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88(15):3275-3281. https://doi.org/10.1002/JNR.22495
Spronk E, Sykes G, Falcione S, et al. Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. Front Neurol. 2021;12:661955. https://doi.org/10.3389/FNEUR.2021.661955
Poljakovic Z, Supe S, Ljevak J, et al. Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke. Clin Neurol Neurosurg. 2021;207:106767. https://doi.org/10.1016/J.CLINEURO.2021.106767
Xie Y, Brand JE, Jann B. Estimating Heterogeneous Treatment Effects with Observational Data. Sociol Methodol. 2012;42(1):314-347. https://doi.org/10.1177/0081175012452652
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. https://doi.org/10.1056/NEJMOA0804656
Whiteley WN, Slot KB, Fernandes P, et al. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43(11):2904-2909. https://doi.org/10.1161/STROKEAHA.112.665331
Sun J, Lam C, Christie L, et al. Risk factors of hemorrhagic transformation in acute ischaemic stroke: A systematic review and meta-analysis. Front Neurol. 2023;14:1079205. https://doi.org/10.3389/FNEUR.2023.1079205
Kalinin MN, Khasanova DR, Ibatullin MM. The hemorrhagic transformation index score: a prediction tool in middle cerebral artery ischemic stroke. BMC Neurol. 2017;17:177. https://doi.org/10.1186/S12883-017-0958-3
de Andrade JBC, Mohr JP, Ahmad M, et al. Accuracy of predictive scores of hemorrhagic transformation in patients with acute ischemic stroke. Arq Neuropsiquiatr. 2022;80(5):455-461. https://doi.org/10.1590/0004-282X-ANP-2021-0091
Fu CH, Chen CH, Lin CH, et al. Comparison of risk scores in predicting symptomatic intracerebral hemorrhage after endovascular thrombectomy. J Formos Med Assoc. 2022;121(7):1257-1265. https://doi.org/10.1016/J.JFMA.2021.09.005
StataCorp. Stata: release 17. Statistical software. Stata meta-analysis reference manual. Published online 2021. Accessed January 8, 2024. https://www.stata.com/manuals17/meta.pdf
Imai K, Ratkovic M. Estimating treatment effect heterogeneity in randomized program evaluation. Ann Appl Stat. 2013;7(1):443-470. https://doi.org/10.1214/12-AOAS593
Ling Y, Upadhyaya P, Chen L, et al. Emulate randomized clinical trials using heterogeneous treatment effect estimation for personalized treatments: Methodology review and benchmark. J Biomed Inform. 2023;137:104256. https://doi.org/10.1016/J.JBI.2022.104256
Raghavan S, Josey K, Bahn G, et al. Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control. Ann Epidemiol. 2022;65:101-108. https://doi.org/10.1016/J.ANNEPIDEM.2021.07.003
Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Stroke. 2001;32(3):669-674. https://doi.org/10.1161/01.STR.32.3.669
Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke. 2002;33(6):1545-1550. https://doi.org/10.1161/01.STR.0000018684.86293.AB
Kalinin MN, Khasanova DR. Heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy: post hoc analysis of the CEREHETIS trial. Front Pharmacol. 2024;14:1288718. https://doi.org/10.3389/fphar.2023.1288718
Libman RB, Kwiatkowski TG, Hansen MD, et al. Differences between anterior and posterior circulation stroke in TOAST. Cerebrovasc Dis. 2001;11(4):311-316. https://doi.org/10.1159/000047659
Sarikaya H, Arnold M, Engelter ST, et al. Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke. Stroke. 2011;42(9):2498-2502. https://doi.org/10.1161/STROKEAHA.110.607614
Merwick Á, Werring D. Posterior circulation ischaemic stroke. BMJ. 2014;348:g3175. https://doi.org/10.1136/BMJ.G3175
Sung SF, Chen CH, Chen YW, et al. Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis: stroke territory as a potential pitfall. J Neurol Sci. 2013;335(1-2):96-100. https://doi.org/10.1016/J.JNS.2013.08.036
Kalinin MN, Khasanova DR, Ibatullin MM. A comprehensive assessment of brain perfusion data in patients with acute ischemic stroke for prediction of hemorrhagic transformation. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(3-2):24-36. (In Russ.). https://doi.org/10.17116/JNEVRO201911903224
Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I-LXII. https://doi.org/10.1177/2396987321989865
Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020;395(10227):878-887. https://doi.org/10.1016/S0140-6736(20)30258-0
Spertus JA, Decker C, Gialde E, et al. Precision medicine to improve use of bleeding avoidance strategies and reduce bleeding in patients undergoing percutaneous coronary intervention: prospective cohort study before and after implementation of personalized bleeding risks. BMJ. 2015;350:h1302. https://doi.org/10.1136/BMJ.H1302
Yoshimura S, Sakai N, Yamagami H, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022;386(14):1303-1313. https://doi.org/10.1056/NEJMOA2118191
Huo X, Ma G, Tong X, et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N Engl J Med. 2023;388(14):1272-1283. https://doi.org/10.1056/NEJMOA2213379
Sarraj A, Hassan AE, Abraham MG, et al. Trial of Endovascular Thrombectomy for Large Ischemic Strokes. N Engl J Med. 2023;388(14):1259-1271. https://doi.org/10.1056/NEJMOA2214403
Imai K, Strauss A. Estimation of Heterogeneous Treatment Effects from Randomized Experiments, with Application to the Optimal Planning of the Get-Out-the-Vote Campaign. Political Analysis. 2011;19(1):1-19. https://doi.org/10.1093/PAN/MPQ035
Baldwin JR, Pingault JB, Schoeler T, et al. Protecting against researcher bias in secondary data analysis: challenges and potential solutions. Eur J Epidemiol. 2022;37(1):1-10. https://doi.org/10.1007/S10654-021-00839-0

Close metadata